New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Millions more senior citizens and lower-income Americans could obtain coverage for costly anti-obesity drugs under a proposal ...
Wall Street Journal on MSN2d
Amgen Obesity Drug Cut Weight In Closely Watched StudyA highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.
Investor's Business Daily on MSN2d
Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity TreatmentAmgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback